Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Recruiting now · Phase 2

Conditions studied: Nasopharyngeal Cancer

In brief

Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.

Key facts

Study ID: NCT04875611
Run by: Maria Sklodowska-Curie National Research Institute of Oncology
People needed: 32
Starts: 2021-08-26
Expected to finish: 2025-12-31
Last updated by the study team: 2025-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age > 18 years old
Histological or cytological documentation of squamous cell carcinoma.
Primary tumor location in nasopharynx
Previous, documented failure on platinum-based chemotherapy or progression of the disease during platinum-based chemotherapy
Tumor recurrence (local or nodal) or generalization (metastasis) occurence during or within 6 months after previous platinum-based chemotherapy
ECOG(Eastern Cooperative Oncology Group) performance scale 0-1
Participant is willing and able to give informed consent for participation in the study and agrees to undergo all follow up visit and planned procedures.

You may not qualify if…

Known active central nervous system metastases.
Presence of renal insufficiency defined as eGFR(estimated glomerular filtration rate) < 30 ml/min/m2
Presence of liver disfunction, defined as level of AST(aspartate aminotransferase) and /or ALT(alanine aminotransferase) > 2,5 x ULN(upper limits of normal) (> 5 x ULN in patients with documented liver metastases); total bilirubin > 1,5 xULN ( bilirubin > 1,5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is < 35%) or albumin < 2,5 g/dL
Abnormalities in blood count such as: hemoglobin < 9 g/dl, platelets < 100 x 109 /L, Absolute Neutrophil Count (ANC) <1,0 x 109 /L
Ejection fraction in echocardiography < 50%
History of active autoimmune diseases except for type I diabetes, hypothyroidism (treated only with hormone supplementation), psoriasis, albinism.
Patient with diagnosed mental disorder preventing, in Investigator's opinion, from participating in a clinical trial.
Pregnancy or breastfeeding.
Female with childbearing potential or male participant with female partner of childbearing potential, who is unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the entire clinical trial period and for 5 months after the end of treatment (last infusion)
Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
Patient is currently participating in another clinical trial.
Active infection, which significantly affects the patient's clinical condition and requires treatment.
Patient with prior bone marrow or solid organ transplantation.
Patient requires immunosuppressive agents, including steroids (daily dose of prednisone or equivalent > 10 mg)
Known immunodeficiency including HIV/AIDS(human immunodeficiency virus/acquired immunodeficiency syndrome) infection.
Patient received any live vaccine within 28 days before enrollment.
Heart Failure - NYHA(New York Heart Association functional classification system) III or IV
Coexistence of active malignant tumor or history of malignant tumor after radical treatment with disease-free period > 2 years, except: cervical cancer in situ/ basocellular skin cancer/prostate cancer, after radical treatment.
Other comorbidities symptoms or conditions that in Investigator's judgement prevent patient from participation in clinical trial.

Where it is running

Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego Szpitala Klinicznego w Białymstoku — Bialystok, Poland (enrolling)
Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu Medycznego — Gdansk, Poland (enrolling)
Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach — Gliwice, Poland (enrolling)
Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum Onkologii — Kielce, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.